摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3,4-dimethoxyphenyl)-4-cyanocyclohexanone | 51533-65-4

中文名称
——
中文别名
——
英文名称
4-(3,4-dimethoxyphenyl)-4-cyanocyclohexanone
英文别名
4-Cyano-4-(3',4'-dimethoxyphenyl)cyclohexanone;1-(3,4-dimethoxy-phenyl)-4-oxo-cyclohexanecarbonitrile;1-(3,4-Dimethoxy-phenyl)-4-oxo-cyclohexancarbonitril;4-cyano-4-(3,4-dimethoxyphenyl)cyclohexanone;4-Cyano-4-(3,4-dimethoxyphenyl)-cyclohexanon;1-(3,4-Dimethoxyphenyl)-4-oxocyclohexanecarbonitrile;1-(3,4-dimethoxyphenyl)-4-oxocyclohexane-1-carbonitrile
4-(3,4-dimethoxyphenyl)-4-cyanocyclohexanone化学式
CAS
51533-65-4
化学式
C15H17NO3
mdl
——
分子量
259.305
InChiKey
DGEFSVRXOCLHAY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    114-116 °C
  • 沸点:
    439.0±45.0 °C(Predicted)
  • 密度:
    1.16±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    59.3
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:930313e6b8a523cce273f691e6797249
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    4-(3,4-dimethoxyphenyl)-4-cyanocyclohexanone 在 sodium tetrahydroborate 、 对甲苯磺酸 作用下, 以 甲醇甲苯 为溶剂, 反应 50.0h, 生成 1-(3,4-dimethoxyphenyl)-t-4-(methylamino)-r-1-cyclohexanecarbonitrile
    参考文献:
    名称:
    维拉帕米类似物具有受限的分子柔性。
    摘要:
    设计了三种具有受限柔韧性的类似物,以研究维拉帕米与慢钙通道相互作用期间的活性构象。因此,顺式和反式-1-(3,4-二甲氧基苯基)-4- [N- [2-(3,4-二甲氧基-苯基)乙基] -N-甲基氨基] -r-1-环己烷腈(5a和5b ),合成了将维拉帕米结构插入环己烷或哌啶环的4-(3,4-二甲氧基苯基)-N- [2-(3,4-二甲氧基苯基)乙基] -4-氰基哌啶。用NMR和理论方法进行构象分析,并在豚鼠主动脉条上测试了慢钙通道拮抗作用。即使它们能够达到非常接近于维拉帕米和类似化合物所建议的最低能量构象的构象,其化合物的效力也比母体化合物低约100倍。
    DOI:
    10.1021/jm00111a043
  • 作为产物:
    描述:
    3,4-二甲氧基苯乙腈sodium hydroxide四丁基硫酸氢铵 、 sodium hydride 、 sodium chloride 作用下, 以 乙二醇二甲醚二甲基亚砜 为溶剂, 反应 9.5h, 生成 4-(3,4-dimethoxyphenyl)-4-cyanocyclohexanone
    参考文献:
    名称:
    (±)-半膜的简单有效合成
    摘要:
    描述了使用双迈克尔加成法并且作为总收率18%的关键步骤的(±)-膜1的简单有效合成方法。
    DOI:
    10.1016/j.tetlet.2004.05.021
  • 作为试剂:
    描述:
    1-(4-氯苯基)-4-氧代环己甲腈对甲苯磺酸 作用下, 以 乙醚4-(3,4-dimethoxyphenyl)-4-cyanocyclohexanone乙二醇 为溶剂, 以90%的产率得到8-(3,4-dimethoxy-phenyl)-1,4-dioxa-spiro[4.5]decane-8-carbonitrile
    参考文献:
    名称:
    4-Amino-4-phenylcyclohexanone ketal compositions and process of use
    摘要:
    一类新的4-氨基-4-芳基环己酮,它们的缩醛和酸盐已经合成,并发现对于缓解动物的疼痛很有用。它们的镇痛活性似乎是很高的,并且一些还表现出对镇痛引起的心血管、呼吸和行为抑制有用的麻醉拮抗活性。其中几种显示出混合的镇痛和麻醉拮抗活性。该类化合物的首选化合物是4-(间羟基苯基)-4-二甲氨基环己酮乙二醚缩醛,以及4-(间羟基苯基)-4-(正丁基甲基氨基)环己酮乙二醚缩醛,作为游离碱和其盐酸盐形式。描述了合成和中间体的过程。披露了单位剂量形式和治疗方法。
    公开号:
    US04065573A1
点击查看最新优质反应信息

文献信息

  • Desymmetrisation of 4,4-disubstituted cyclohexanones by enzyme-catalysed resolution of their enol acetates
    作者:Graham Allan、Andrew J. Carnell、Maria Luisa Escudero Hernandez、Alan Pettman
    DOI:10.1039/b005466f
    日期:——
    Enol acetates 3–10 derived from prochiral 4,4-disubstituted cyclohexanones can be resolved with Pseudomonas fluorescens lipase to give enantiomerically pure (>99% ee) enol esters by transesterification with n-BuOH. The product ketones are prochiral and can easily be recycled giving an overall desymmetrisation of the ketone. Highest selectivity was obtained for substrates containing a 4-cyano and 4-aryl or a 4-benzyloxy substituent. The methodology was compared to asymmetric deprotonation–enolate trapping using the chiral base (S,S)-bis(α-methylbenzyl)amide which gave low (54–64%) ee’s for this class of ketones.
    来自对称的4,4-二取代环己酮的醇乙酸酯3-10可以通过荧光假单胞菌脂肪酶进行分离,以转酯化反应与正丁醇生成对映体纯度>99% ee的醇酯。生成的酮是对称的,可以很容易地循环利用,从而实现酮的整体去对称化。对于含有4-氰基和4-芳基或4-苄氧基取代基的底物,获得了最高的选择性。该方法与使用手性碱(S,S)-双(α-甲基苯甲酰)胺的非对称去质子化-烯醇捕获进行了比较,该方法在这一类酮中获得了较低的对映体纯度(54-64% ee)。
  • Bisarylamines
    申请人:Rorer Pharmaceutical Corporation
    公开号:US04795757A1
    公开(公告)日:1989-01-03
    Compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof, wherein: Ar is phenyl, naphthyl, heteroaryl, indole, or fused arylcycloalkyl optionally substituted with hydroxy, halo, CF.sub.3, NO.sub.2, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or aryloxy; A and A' are each hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy or aryloxy; X is cyano, nitro, COOR, SR, SOR or SOOR; R is H, C.sub.1-6 alkyl or aryl; n n' and n" are each 0 to 4; and m, m' and m" are each 1 to 4, have calcium channel blocking activity.
    该化合物的结构式如下:##STR1##及其药用盐,其中:Ar为苯基、萘基、杂环芳基、吲哚基或融合芳基环烷基,可选择地取代为羟基、卤素、三氟甲基、硝基、C.sub.1-6烷基、C.sub.1-6烷氧基或芳氧基;A和A'均为氢、C.sub.1-6烷基、C.sub.1-6烷氧基、羟基或芳氧基;X为氰基、硝基、COOR、SR、SOR或SOOR;R为H、C.sub.1-6烷基或芳基;n、n'和n"均为0至4;m、m'和m"均为1至4,具有钙通道阻滞活性。
  • The first ionic liquid-promoted Kabbe condensation reaction for an expeditious synthesis of privileged bis-spirochromanone scaffolds
    作者:M. Muthukrishnan、U.M.V. Basavanag、Vedavati G. Puranik
    DOI:10.1016/j.tetlet.2009.03.104
    日期:2009.6
    A variety of privileged bis-spirochromanones were synthesized for the first time from 4,6-diacetyl resorcinol in one-pot by carrying out the Kabbe condensation in room temperature ionic liquid [bbim]Br.
    通过在室温离子液体[bbim] Br中进行Kabbe缩合反应,由一锅中的4,6-二乙酰基间苯二酚首次合成了多种特有的双-螺并铬烷酮。
  • 4-Pyrrolidino-cyclohexanone ketals
    申请人:The Upjohn Company
    公开号:US04180584A1
    公开(公告)日:1979-12-25
    A class of new 4-amino-4-arylcyclohexanones, their ketals, and acid addition salts have been synthesized and found to be useful for relieving pain in animals. Their analgesic activity appears to be of high order, and in addition some exhibit narcotic antagonist activity that is useful in modifying the cardiovascular, respiratory, and behavioral depression caused by other analgesics. Several show mixed analgesic and narcotic antagonist activity. Preferred compounds of the class are 4-(m-hydroxyphenyl)-4-dimethylaminocyclohexanone ethylene ketal, and 4-(m-hydroxyphenyl)-4-(n-butylmethylamino)cyclohexanone ethylene ketal as free bases and as their hydrochloride salts. Processes for snythesis and intermediates are described. Unit dosage forms and therapeutic treatments are disclosed.
    一类新的4-氨基-4-芳基环己酮、它们的缩酮和酸加成盐已被合成并发现对缓解动物疼痛有用。它们的镇痛活性似乎是高级别的,另外一些表现出麻醉拮抗活性,有助于改变其他镇痛剂引起的心血管、呼吸和行为抑制。几种显示出混合的镇痛和麻醉拮抗活性。该类化合物的首选物是4-(间羟基苯基)-4-二甲氨基环己酮乙二醇缩酮和4-(间羟基苯基)-4-(正丁基甲基氨基)环己酮乙二醇缩酮,作为自由碱和它们的盐酸盐。描述了合成和中间体的过程。揭示了单元剂量形式和治疗方法。
  • 4-Arylcyclohexylamines
    申请人:The Upjohn Company
    公开号:US03979444A1
    公开(公告)日:1976-09-07
    The invention relates to novel 4-hydroxymethyl(acyloxymethyl and methyl)-4-arylcyclohexylamines embraced by the formula ##SPC1## Wherein Ar is an aromatic ring selected from the group consisting of phenyl and naphthyl, each of which has from zero through three substituents independently selected from the group consisting of fluorine, chlorine, bromine, lower alkyl of one through three carbon atoms, lower alkoxy of one through three carbon atoms, and lower alkylthio of one through three carbon atoms; Z is selected from the group consisting of hydrogen, hydroxy and lower acyloxy of one through four carbon atoms; .about. is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the stereoconfiguration of the linkage connecting the cyclohexane ring and CH.sub.2 Z is cis to the amino group, the linkage connecting the cyclohexane and Ar rings is trans, and vice versa; R.sup.1 is selected from the group consisting of hydrogen and lower alkyl of one through three carbon atoms; R.sup.2 is selected from the group consisting of hydrogen, lower alkyl of one through three carbon atoms, ##EQU1## WHEREIN N IS 2 THROUGH 5 AND Ar has the same meaning as above; R.sup.1 and R.sup.2 taken together with --N< is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and pharmacologically acceptable acid addition salts thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (I) and novel derivatives thereof. The administration to humans and animals of the novel compounds (I) depresses their central nervous systems and lowers their blood pressures.
    本发明涉及一种新型的4-羟甲基(酰氧甲基和甲基)-4-芳基环己胺,其公式为##SPC1##其中Ar是从苯基和萘基选择的芳香环,每个环都有从0到3个取自氟、氯、溴、1至3个碳原子的低级烷基、1至3个碳原子的低级烷氧基和1至3个碳原子的低级烷基硫基的官能团自由置换;Z选择自氢、羟基和1至4个碳原子的低级酰氧基的官能团自由置换;∼是表示顺式和反式立体构型及其混合物的通用表达式,但当连接环己烷环和CH.sub.2 Z的立体构型为顺式时,连接环己烷环和Ar环的立体构型为反式,反之亦然;R.sup.1选择自氢和1至3个碳原子的低级烷基的官能团自由置换;R.sup.2选择自氢、1至3个碳原子的低级烷基、## EQU1##其中N为2至5,Ar具有与上述相同的含义;R.sup.1和R.sup.2与--N <一起取代为选自未取代和取代的吡咯烷基、哌啶烷基、六亚甲基亚胺基、吗啉基和哌嗪基的饱和杂环氨基基团;以及其药学上可接受的酸加盐。本发明还涉及上述新型化合物(I)及其新型衍生物的中间体和制备方法。将新型化合物(I)用于人类和动物可以抑制其中枢神经系统并降低其血压。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐